

February 25, 2020



# Aptose to Release Fourth Quarter and Year End December 31, 2019 Financial Results and Hold Conference Call on March 10, 2020

SAN DIEGO and TORONTO, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will release its financial results for the quarter and year ended December 31, 2019, on Tuesday, March 10, 2020 after the close of the market.

## ***Conference Call & Webcast:***

**Date:** Tuesday, March 10, 2020  
**Time:** 5:00 PM Eastern Time  
**Dial In - Toll-Free:** 1 844-882-7834  
**Dial In - International:** 1 574-990-9707  
**Passcode:** 1097606  
**Webcast:** [LINK](#)

## ***Replay available through March 17, 2020:***

**Dial In - Toll-Free:** 1 855-859-2056  
**Dial In - International:** 1 404-537-3406  
**Replay Passcode:** 1097606

The live conference call can also be accessed through a link on the Investor Relations section of Aptose's website at <https://www.aptose.com/investors/news-events/ir-calendar>. An archived version of the webcast along with a transcript will be available on the company's website for 30 days.

The press release, the financial statements and the management's discussion and analysis for the quarter ended and year ended December 31, 2019 will be available on SEDAR at [www.sedar.com](http://www.sedar.com) and EDGAR at [www.sec.gov/edgar.shtml](http://www.sec.gov/edgar.shtml).

## **About Aptose Biosciences**

Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage investigational products for hematologic malignancies: CG-806, an oral, first-in-class

mutation-agnostic FLT3/BTK kinase inhibitor, is in a Phase 1 trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and non-Hodgkin lymphoma (NHL), who have failed or are intolerant to standard therapies; APTO-253, the only clinical stage agent that directly targets the MYC oncogene and suppresses its expression, is in a Phase 1b clinical trial for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) or high risk myelodysplastic syndrome (MDS). For further information, please visit [www.aptose.com](http://www.aptose.com).

For further information, please contact:

**Aptose Biosciences Inc.**

Greg Chow  
Senior Vice President, CFO  
650-718-5028  
[gchow@aptose.com](mailto:gchow@aptose.com)

**LifeSci Advisors, LLC**

Dan Ferry, Managing Director  
617-535-7746  
[Daniel@LifeSciAdvisors.com](mailto:Daniel@LifeSciAdvisors.com)

**SMP Communications**

Susan Pietropaolo  
201-923-2049  
[susan@smpcommunications.com](mailto:susan@smpcommunications.com)



Source: Aptose Biosciences, Inc.